CDK4 and acute myeloid leukemia: To this end, we studied whether the CDK4/6 inhibitors palbociclib and abemaciclib, and PI3K inhibitors are effective against AML cell lines expressing activating FLT3-ITD mutants (MOLM-13, MOLM-14 and MV4-11 cell lines; an additonal cell line expressing wild type FLT3 is also used in some experiments).